Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Inactivated Influenza A/H7N7 Vaccine in Healthy Adults
NCT00546585Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2008
- Primary completion
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza a/h7n7 vaccine in influenza (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse event (AE) or serious adverse event (SAE) information at 7 months, Proportion of subjects achieving a serum neutralizing antibody titer of greater than or equal to 40 against the influenza A/H7N7 virus at Day 56 and 4 more. Started Mar 2008; status: completed.
02
Drugs
influenza a/h7n7 vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00546585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546585.